Core Insights - Praxis Precision Medicines, Inc. will report its financial results for Q4 and the full year ended December 31, 2025, on February 19, 2026, before the market opens [1] - The company will host a conference call and live webcast on the same day at 8:00 am ET to review the financial results and provide a corporate update [2] - Praxis has a diversified CNS portfolio with multiple programs across movement disorders and epilepsy, including four late-stage product candidates [4] Company Overview - Praxis Precision Medicines is a leading CNS precision neuroscience biopharmaceutical company focused on developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance [4] - The company utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to translate genetic insights into therapeutic development [4] - Praxis is actively participating in investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, and the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [5]

Core Insights - Praxis Precision Medicines, Inc. has appointed Dr. Orrin Devinsky as Head of Clinical Strategy, a newly created leadership role, reflecting the company's commitment to advancing its clinical strategy and global medical affairs [1][3] Group 1: Appointment and Role - Dr. Devinsky is a highly influential figure in epilepsy and clinical neuroscience, with over 40 years of experience and significant contributions to the development of transformative therapies [2] - In his new role, Dr. Devinsky will guide program architecture, evidence generation, and external scientific engagement as Praxis advances its late-stage portfolio toward commercialization [3] Group 2: Contributions and Achievements - Dr. Devinsky has been instrumental in pivotal clinical trials leading to the FDA approval of cannabidiol therapy for various severe epilepsy syndromes, marking a new therapeutic class for rare epilepsies [4] - His scientific contributions include over 500 peer-reviewed publications and 16 issued patents in areas such as epilepsy therapeutics and drug delivery [4] Group 3: Organizational Impact - Dr. Devinsky has founded or co-founded several impactful organizations in the epilepsy community, including FACES and the North American SUDEP Registry, enhancing the understanding of epilepsy-related mortality [5] - His career has been recognized with prestigious awards, including the American Epilepsy Society J. Kiffin Penry Award and the 2025 Epilepsy Foundation Lifetime Accelerator Award [5] Group 4: Company Vision - Dr. Devinsky expressed confidence in Praxis's scientific rigor and long-term vision, highlighting the company's comprehensive precision-based pipelines for epilepsy therapies [6] - Praxis is focused on translating genetic insights into therapies for CNS disorders, utilizing proprietary platforms for drug development [7]

Core Insights - Praxis Precision Medicines, Inc. has announced key leadership appointments to enhance its strategic direction as it prepares for commercial launch and late-stage development [1][2] Leadership Appointments - Jeffrey B. Kindler has been appointed to the board, bringing extensive experience in enterprise leadership and strategic transactions from his tenure as former chairman and CEO of Pfizer [3] - Stuart Arbuckle joins the board with a strong background in global commercial success, having spent 13 years at Vertex Pharmaceuticals, where he played a pivotal role in the company's growth [5] - Megan Sniecinski has been promoted to Chief Operating Officer, responsible for operationalizing the company's growth strategy and overseeing program strategy and operations [8][9] - Dr. Steven Petrou has been promoted to President of Research & Development, reflecting the company's transition into late-stage development with multiple programs advancing toward commercialization [9][10] Strategic Vision - The leadership changes are aimed at optimizing value-creation pathways for Praxis as it enters a critical phase of growth, focusing on commercial launch planning and execution readiness [2][4] - The company is positioned to become a leading CNS company with a pipeline of multi-billion dollar drugs and innovative therapies targeting severe neurological disorders [7] Pipeline and Development - Praxis has a diversified CNS portfolio, including multiple clinical-stage product candidates, and is leveraging genetic insights to develop therapies for both rare and prevalent neurological disorders [12]

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance [1][3] - The company will participate in three upcoming investor conferences, providing opportunities for one-on-one meetings with interested investors [1][4] Company Overview - Praxis utilizes genetic insights from epilepsy to develop therapies for CNS disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - The company has a diversified portfolio that includes multiple programs targeting epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - Praxis will present at the Baird 2025 Global Healthcare Conference on September 9th from 9:00-9:35am EDT [4] - A fireside chat is scheduled for September 10th at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30am EDT [4] - A virtual corporate presentation will take place on September 18th at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit from 3:00-3:30pm EDT [4]

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders through genetic insights [1][2] - The company will have its CEO Marcio Souza participate in a virtual fireside chat hosted by Truist Securities on August 5, 2025 [1] Company Overview - Praxis specializes in translating insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance [2] - The company utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to develop therapies for both rare and prevalent neurological disorders [2] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, featuring four clinical-stage product candidates [2]

Core Insights - Praxis Precision Medicines, Inc. is set to report topline results from the RADIANT trial of vormatrigine and its financial results for Q2 2025 on August 4, 2025, before market opening [1] - A live webcast will be hosted on the same day at 8:30am ET, accessible via a registration link and available for replay for 90 days [2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, utilizing genetic insights [3] - The company employs proprietary platforms, Cerebrum™ for small molecules and Solidus™ for antisense oligonucleotides, to target shared biological mechanisms in the brain [3] - Praxis has a diversified CNS portfolio with multiple programs addressing epilepsy and movement disorders, featuring four clinical-stage product candidates [3]

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - The company will participate in three investor conferences, including a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20 at 9:30 am ET [4] - Praxis management will also attend the Mizuho Neuro & Ophthalmology Summit in New York City on May 21 [4] - A corporate overview will be presented at the Jefferies Global Healthcare Conference on June 4 at 8:10 am ET [4] Investor Engagement - The company will be available for one-on-one meetings during all events, encouraging interested investors to contact their representatives [1] - Webcasts of the events will be accessible for 90 days through the "Events & Presentations" page on the company's website [2]